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tiﬁed manner. This study was approved by the institutional
review board of the University of Oklahoma Health Sciences
Center. Patient comorbidity index scores were calculated
within 30 days of transplant using the QxMD Hematopoietic
Cell Transplantation-Speciﬁc Index (HCT-CI) calculator. Kar-
nofsky Performance Status was determined by a physician
during pre-transplant assessment. Additional pre-transplant
data collected included: gender, age at transplant, date of
transplant, donor type, donor source, preparative method,
speciﬁc preparative regimen, disease status at the time of
transplant, disease type, and insurance status. Post-trans-
plant data collected included: survival at 100 days, 1 year,
and 2 years post-transplant, cause of death, presence of
graft-versus-host disease (GVHD), type of GVHD, organ
affected by GVHD, and documented infections. Our results
indicated that higher CMI scores were signiﬁcantly associ-
ated with increased non-relapse mortality in patients
undergoing myeloablative transplant preparative regimens
(P < .001). Lower KPS scores were also signiﬁcantly associ-
ated with poor survival ( P < .001). Insurance was not
signiﬁcantly associated with non-relapse mortality (P > .05).
Finally, 39% of all patient deaths were attributed to disease,
20% of patient deaths were attributed to non-relapse
mortality, while 41% of patients survived.377
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Introduction: Reduced intensity conditioning (RIC) with
alemtuzumab, ﬂudarabine, and melphalan improves the
hematopoietic cell transplant (HCT) outcomes of patients
with hemophagocytic lymphohistiocytosis (HLH). Proximal
dosing of alemtuzumab is associated with a high incidence of
mixed chimerism (MC) whereas distal dosing is associated
with less MC but higher incidences of acute GVHD following
initial graft infusion. We hypothesized that an intermediate
alemtuzumab schedule would optimize the incidences of MC
and acute GVHD.
Methods: Twenty-ﬁve consecutive transplants were per-
formed in patients with HLH or XLP using a RIC regimenwith
a novel intermediate alemtuzumab schedule of 1mg/kg
beginning on day -14. The cumulative incidences of MC and
acute GVHD were compared to 2 retrospective cohorts of
patients with HLH and XLP treated with distal (n¼15) or
proximal (n¼33) alemtuzumab schedules. All patients
received ﬂudarabine 150mg/M2 (1mg/kg if <10kg) divided
over days -8 to -4, and melphalan 140mg/M2 (4.7mg/kg if
<10kg) on day -3. Melphalan was reduced by 50% in one
infant due to concern for toxicity. GVHD prophylaxis con-
sisted of methylprednisolone and cyclosporine or tacrolimus
in all but 2 patients who received methylprednisolone and
MMF. Three patients additionally received methotrexate.
Results: The cumulative incidence of MC was less in the
intermediate alemtuzumab cohort at 34%, versus 72% in theproximal and 40% in the distal cohorts (P ¼ .008). The
cumulative incidence of acute GVHD related to initial graft
infusion (before MC) was 4% in the intermediate cohort and
0% in the proximal cohort (P ¼ .26), versus 13% in the distal
cohort (P ¼ .04, proximal versus distal). There was a trend
toward less overall acute GVHD (following graft infusion or
following intervention for MC) in the intermediate cohort
at 12%, versus 16% and 27% in the proximal and distal cohorts
(P ¼ .55).
Conclusion: This novel 14 day RIC regimen optimizes the
incidences of MC and acute GVHD.378
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Introduction: The allogeneic hematopoietic cell trans-
plantation (alloHCT) remains the only treatment modality
with known curative potential in MDS, AML and CMML. The
5-azacitidine is the ﬁrst line treatment in high-risk MDS that
are not suitable for intensive therapy. On the other hand,
there is not enough evidence for deciding which is the best
option, either 5-azacitidine or induction chemotherapy,
before alloHCT. In a similar way, the 5-azacitidine exposure
in post-alloHCT relapsemay be an attractive alternative, even
though there are not deﬁnite results yet.
Objective: Evaluate the capacity of 5-azacitidine in reducing
or stabilizing the disease before alloHCT, regarding associ-
ated toxicity, and its role in post-alloHCT relapses.
Patients And Methods: We retrospectively reviewed 36
patients who underwent alloHCT for high-risk MDS, AML
and CMML between October 2006 and September 2012 in
our center and who received 5-azacitidine before and/or
after alloHCT.
Results: 30 patients received 5-azacitidine pre-alloHCT, 22
were MDS (73%), 6 AML (22%) and 2 CMML (7%), with high-
risk cytogenetic (according to IPSS-R) in one third of them.
The median of cycles was 5 (1-12), using the conventional
dose and schedule, and presenting usual toxicity in only 38%
of cases. Two thirds of evaluable patients achieved complete
remission (CR) or partial response (PR) and 26% progressed.
83% of patients underwent alloHCT in some type of response
and 17% in progression. The alloHCT characteristics were:
median of age of 56 (35-67), peripheral blood as source of
stem cells in 93%, related donor in 62%, and reduced-inten-
sity conditioning in most cases (83%). At day +100, 82% of
patients achieved CR and 18% had progressed. The global
post-alloHCT relapse rate was 33%. The 2-years overall
survival (OS) and event-free survival (EFS) were 66% and 50%,
respectively. At 1 year, the relapse-free survival (RFS) was
65%, without having reached the median follow-up. We did
not observe any signiﬁcant statistical differences in OS after
taking into account the following factors: sex, diagnosis,
previous lines of treatment, response to 5-azacitidine,
response at alloHCT and type of donor. However, cytogenetic
risk did signiﬁcantly inﬂuence survival in terms of OS, EFS
and RFS, the same as source of stem cells, type of condi-
tioning regimen and response at day +100 in OS. 16 patients
received 5-azacitidine after post-alloHCT relapse with
a median of cycle of 3.5 (1-19), reduced dose in some cases
and limited toxicity (42%). The median of days after alloHCT
to the beginning of treatment was 152 (32-529). Two thirds
